Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study
Academic Article
Publication Date:
2022
Short description:
Use of Dupilumab for 543 Adult Patients with Moderate-To-Severe Atopic Dermatitis: A Multicenter, Retrospective Study / Nettis, E., Ferrucci, S.M., Ortoncelli, M., Pellacani, G., Foti, C., Di Leo, E., Patruno, C., Rongioletti, F., Argenziano, G., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Romita, P., Di Bona, D., Nisticò, S.P., Piras, V., Calabrese, G., Detoraki, C., et al.. - In: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY. - ISSN 1018-9068. - 32:2(2022), p. 0. [10.18176/jiaci.0641]
abstract:
Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date.
Iris type:
1.1 Articolo in rivista
Keywords:
Atopic dermatitis; Dupilumab; Multicentric real-life study
List of contributors:
Nettis, E; Ferrucci, S M; Ortoncelli, M; Pellacani, G; Foti, C; Di Leo, E; Patruno, C; Rongioletti, F; Argenziano, G; Macchia, L; Tavecchio, S; Napolitano, M; Ribero, S; Bonzano, L; Romita, P; Di Bona, D; Nisticò, S P; Piras, V; Calabrese, G; Detoraki, C; Carbonara, M; Fabbrocini, G
Published in: